ETX0282 is an oral prodrug of a class A, C, and D serine β-lactamase inhibitor in clinical development for drug-resistant enterobacterial infections in combination with the beta-lactam drug cefpodoxime proxetil. Impressively ETX0282 had no observed adverse effect levels (NOAELs) of 500 mg/kg/day and 400 mg/kg/day in rat and dog, respectively, [...]
< 1 minute read
Sep. 18, 2021
ETX0282: An Oral Prodrug of Serine-Lactamase Inhibitor
ETX0282
oral prodrug of serine _-lactamase inh. in dev. for multidrug resistant bact. infection from optimization of prior _-lactamase inh. J. Med. Chem., Jul. 24, 2020 Entasis Therapeutics, Waltham, MA
Loading...
